Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.
first published: Dec 20, 2013 06:07 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty reclaims 25,300, registers over 1% gain this week | Closing Bell
Live: Will Nifty bulls aim to break 25,250 after strong TCS Q2? | Opening Bell
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
